New York, June 1, 2026, 14:07 EDT
- AIM shares more than doubled in heavy afternoon trading after a pancreatic-cancer trial update.
- The company said the final planned DURIPANC subject met enrollment criteria, with treatment planned for mid-June.
- A December readout remains the next hard test for Ampligen.
AIM ImmunoTech Inc. shares more than doubled on Monday after the drug developer said the final planned subject in its Phase 2 DURIPANC pancreatic-cancer trial had met enrollment criteria, putting the study ahead of its earlier July target.
The stock was recently at 92.79 cents, up 52.01 cents on the session, on volume of more than 312 million shares. Its intraday range ran from 42.33 cents to $1.215, a wide move even by small biotech standards.
The update matters now because AIM’s lead drug, Ampligen, is moving toward a December 2026 evaluation of the study’s main endpoint: clinical benefit rate, a measure of how many patients have stable disease, partial response or complete response after treatment. The company said the final planned subject is scheduled for mid-June treatment, barring pre-treatment disqualification.
AIM Chief Executive Thomas K. Equels called it an “important execution milestone” for DURIPANC. The company said it expects its next interim report in the next two to three weeks.
DURIPANC is testing Ampligen, also known as rintatolimod, with AstraZeneca’s Imfinzi, an immune checkpoint inhibitor that helps the immune system recognize cancer cells. The trial is in metastatic pancreatic cancer patients whose disease is stable after FOLFIRINOX, a standard chemotherapy regimen.
In February, AIM had guided to complete subject enrollment in July, finish full Ampligen dosing in August and evaluate the primary endpoint in December. Monday’s update pulls the enrollment piece forward, though it does not change the main data test.
The rally also came against a soft biotech tape. The SPDR S&P Biotech ETF was down about 1.6%, while the broader SPDR S&P 500 ETF was up about 0.4%, underscoring how stock-specific the AIM move was.
Pancreatic cancer has become a busy field for investors after Revolution Medicines reported that daraxonrasib nearly doubled median overall survival versus chemotherapy in a Phase 3 study of previously treated metastatic disease. Brian M. Wolpin of Dana-Farber, the trial’s principal investigator, said “new treatment options are urgently needed” for these patients. Revolution Medicines
Oncolytics Biotech also said Monday it plans more preclinical work on pelareorep with RAS-targeted approaches, including in pancreatic ductal adenocarcinoma models. That keeps AIM in a crowded, fast-moving niche, even though its Ampligen approach is different and remains earlier in development.
AIM’s own balance sheet remains part of the trade. In a May 20 securities filing, the company said it agreed to sell 7.5 million shares at 32.5 cents each and issue warrants, which are securities allowing holders to buy stock later, for up to about 15.0 million more shares at the same exercise price. The registered offering was expected to raise about $2.4 million before expenses.
That is the risk paragraph investors cannot skip. Faster enrollment is not trial success, the last subject still must clear pre-treatment conditions, and the key efficacy readout is months away. Further financing or warrant exercises could also dilute existing holders, while a weak interim update would leave the stock exposed after Monday’s surge.
For now, the market is paying for time gained. The next question is whether AIM can turn that into data strong enough to support its planned Phase 3 push.
